Abstract:Potential conflict of interest: Nothing to report. To the Editor: We read with great interest the article by Bessho et al., who demonstrated that, among the 15 genes uniquely expressed in the liver of patients with biliary atresia (BA), IL8 and LAMC2 were sufficient to distinguish subjects with BA from patients with non‐BA controls, with an accuracy of 95%.1 They conclude that hepatic expression of these two genes may serve as a biomarker of disease. Whereas we appreciate the findings, we would like to address a few issues that may help further clarify or confirm the findings. First, only 14 patients were included as non‐BA controls; the causes of disease were unknown for 64.3% (n = 9) (Supporting Table 1 of Bessho et al.). Moreover, 21.4% (n = 3) of the non‐BA controls were misclassified by IL8 and LAMC2 as BA (Supporting Table 2 of Bessho et al.). It is conceivable that some non‐BA diseases share a similar genetic signature or phenotypic traits with BA, and exhibit similar hepatic expression profiles. Indeed, as previously demonstrated, the IL‐8 level is higher in the BA and non‐BA groups than in normal controls, and the increased IL‐8 level is associated with the lymphocytic count and the degree of fibrosis in BA.2 Also, it has been known that viral infection can promote IL‐8 expression in the liver, which is associated with chronic liver disease.5 Thus, subjects with virus infection in the non‐BA groups might have a similar level of hepatic IL‐8 expression, compared with those in the BA group. In the present study, whether the false positivity by IL8 and LAMC2 observed in three patients in the non‐BA group was associated with infections with viruses such as rotavirus, cytomegalovirus, etc. is unknown. Second, it has been reported that IL‐8 mRNA increases in the liver, particularly in the late stage of BA (e.g., the degree of fibrosis represented by aspartate aminotransferase‐to‐platelet ratio index) and advanced age, and is associated with persistent jaundice, portal hypertension, and/or an increased inflammation and fibrosis in the liver.3 Thus, it is recommended that the patients included in the study be divided into different groups according to the degree of fibrosis (e.g., aspartate aminotransferase‐to‐platelet ratio index) and age (e.g., ≤60, 61‐90, and > 90days). Therefore, it would be interesting if Bessho et al. were to reassess their data by taking viral infection, the degree of fibrosis, and age into account. Alternatively, a larger case‐controlled study incorporating the above‐mentioned points is required.

A study on the intrahepatic expression of IL-17 in the patients with billary atresla

The Aberrant Expression of HLA-DR in Intrahepatic Bile Ducts in Patients with Biliary Atresia: an Immunohistochemistry and Immune Electron Microscopy Study.

Correlation of Interleukin-33/ST2 Receptor and Liver Fibrosis Progression in Biliary Atresia Patients.

Hepatic Expression of Interleukin 8 in Diagnosing Biliary Atresia

Association of T-helper cell cytokine level with age in patients with biliary atresia: a preliminary study.

Expression of programmed death-1 and its ligands in the liver of biliary atresia

The Correlative Study of the Intra-and Extrahepatic Biliary System Inflammation and Prognosis

Single‐cell and spatial transcriptomics reveal the fibrosis‐related immune landscape of biliary atresia

Identification of Liver Immune Microenvironment-Related Hub Genes in Liver of Biliary Atresia

Expression of HSP47 in Liver Tissue and Sera of Infants with Biliary Atresia and Its Correlation with the Degree of Liver Fibrosis and Prognosis

RETRACTED ARTICLE:Interactions between Th1 cells and Tregs affect regulation of hepatic fibrosis in biliary atresia through the IFN-γ/STAT1 pathway

Study on Relationship between Th17 Cells,Th17 Cytokine and the Inflammatory Activity of Liver Tissue in Posthepatitis B Cirrhosis

IL-17A produced by invariant natural killer T cells and CD3(+)CD56(+)alpha Galcer-CD1d tetramer(-) T cells promote liver fibrosis in patients with primary biliary cholangitis

Immune Characteristics in Biliary Atresia Based on Immune Genes and Immune Cell Infiltration

Infiltration of Polarized Macrophages Associated with Liver Fibrosis in Infants with Biliary Atresia.

Liver Immune Profiling Reveals Pathogenesis and Therapeutics for Biliary Atresia

IL-17A produced by invariant natural killer T cells and CD3+CD56+αGalcer-CD1d tetramer– T cells promote liver fibrosis in patients with primary biliary cholangitis

Upregulation of High Mobility Group Box 1 May Contribute to the Pathogenesis of Biliary Atresia.

Interleukin-17A level in patients with liver cirrhosis and its clinical significances

Immunologic Regulations in the Pathogenesis of Biliary Atresia and Hepatic Fibrosis

Histamine is correlated with liver fibrosis in biliary atresia.